.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Mallinckrodt
US Department of Justice
Johnson and Johnson
AstraZeneca
Cipla
Argus Health
Colorcon
Chinese Patent Office
Fish and Richardson

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,358,240

« Back to Dashboard

Which drugs does patent 9,358,240 protect, and when does it expire?


Patent 9,358,240 protects TYVASO and is included in one NDA. There has been one Paragraph IV challenge on Tyvaso.

This patent has ten patent family members in six countries.

Summary for Patent: 9,358,240

Title:Treprostinil administration by inhalation
Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Inventor(s): Olschewski; Horst (Graz, AT), Roscigno; Robert (Chapel Hill, NC), Rubin; Lewis J. (LaJolla, CA), Schmehl; Thomas (Giessen, DE), Seeger; Werner (Giessen, DE), Sterritt; Carl (Weybridge, GB), Voswinckel; Robert (Giessen, DE)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:12/591,200
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
United Therap
TYVASO
treprostinil
SOLUTION;INHALATION022387-001Jul 30, 2009RXYesYes► Subscribe► Subscribe METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,358,240

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,339,507Treprostinil administration by inhalation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,358,240

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan5797376► Subscribe
Japan2014114269► Subscribe
Japan2016006066► Subscribe
South Korea20090007797► Subscribe
South Korea101390579► Subscribe
European Patent Office2026816► Subscribe
Japan2009537246► Subscribe
China101495122► Subscribe
Canada2654492► Subscribe
World Intellectual Property Organization (WIPO)2007134292► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Teva
Dow
Novartis
McKesson
AstraZeneca
Mallinckrodt
Covington
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot